5-Isobutyl-1-phenyl-3-[3-(2-phenylacetyl)-3-azabicyclo[3.1.0]hexane-6-carboxamido]methyl-1H-pyrazole

ID: ALA4451905

Chembl Id: CHEMBL4451905

PubChem CID: 86292750

Max Phase: Preclinical

Molecular Formula: C28H32N4O2

Molecular Weight: 456.59

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(C)Cc1cc(CNC(=O)C2C3CN(C(=O)Cc4ccccc4)CC32)nn1-c1ccccc1

Standard InChI:  InChI=1S/C28H32N4O2/c1-19(2)13-23-15-21(30-32(23)22-11-7-4-8-12-22)16-29-28(34)27-24-17-31(18-25(24)27)26(33)14-20-9-5-3-6-10-20/h3-12,15,19,24-25,27H,13-14,16-18H2,1-2H3,(H,29,34)

Standard InChI Key:  HHBXZUNQLWOTOK-UHFFFAOYSA-N

Associated Targets(Human)

CACNA1G Tclin Voltage-gated T-type calcium channel alpha-1G subunit (1361 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CACNA1H Tclin Voltage-gated T-type calcium channel alpha-1H subunit (1913 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CACNA1B Tclin Voltage-gated N-type calcium channel alpha-1B subunit (743 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP2D6 Tclin Cytochrome P450 2D6 (33882 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP2C9 Tchem Cytochrome P450 2C9 (32119 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP2C19 Tchem Cytochrome P450 2C19 (29246 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP3A4 Tclin Cytochrome P450 3A4 (53859 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 456.59Molecular Weight (Monoisotopic): 456.2525AlogP: 3.63#Rotatable Bonds: 8
Polar Surface Area: 67.23Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 13.85CX Basic pKa: 1.49CX LogP: 3.46CX LogD: 3.46
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.56Np Likeness Score: -0.83

References

1. Kim JH, Nam G..  (2016)  Synthesis and evaluation of 6-pyrazoylamido-3N-substituted azabicyclo[3,1,0]hexane derivatives as T-type calcium channel inhibitors for treatment of neuropathic pain.,  24  (21): [PMID:27591007] [10.1016/j.bmc.2016.06.006]

Source